INSERM

BCV Announces First-In-Human Cases with GECKO System Aimed at Increased Procedural Speed and Reduced Complication in Neurovascular Procedures

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Surgery, Medical Devices, Health, Cardiology, Interventional neuroradiology, Journal of NeuroInterventional Surgery, WSO, CEO, SM, Sorbonne, INSERM, Brain, Doctor of Philosophy, Time, Sale, USD, Intelligent Systems, Intervention, MD, Stroke, FDA, ISIR, World Stroke Organization, Institute, BCV, Catheter, Patient, Medical device, Medical imaging, Robotics

BCV announces a major step in the development and evaluation of steerable mechatronic guidewires for stroke treatment the GECKO System.

Key Points: 
  • BCV announces a major step in the development and evaluation of steerable mechatronic guidewires for stroke treatment the GECKO System.
  • The first-in-human case was conducted by Michel Piotin, MD, PhD, head of Interventional neuroradiology at Foundation Rothschild Hospital in Paris, France.
  • 3 Current approaches can involve excessive time and devices to obtain access to the stroke location, depending on anatomical complexity.
  • To learn more, please visit www.basecampvascular.com
    Caution: The GECKO System is an investigational device and is not available for commercial sale, worldwide.

The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) Enter a Strategic Partnership for the Study of NASH

Retrieved on: 
Wednesday, September 7, 2022
Beaujon Hospital, Partnership, Vascular disease, Paris Diderot University, CEO, National Institute, Imaging, SIB, Artificial intelligence, Liver, INSERM, Trial of the century, CEA, Seminal vesicles, Pathology, Artificiality, Digital pathology, Commissariat, Physics, Swiss Institute of Bioinformatics, Fatty liver disease, Diagnosis, Diabetes, Medical research, Inflammation, Type 2 diabetes, Fibrosis, GLOBE, Biostatistics, Leadership, Princeton University, NASH, University, Assistance, Data, Patient, QUID, Medical imaging, T2D, Beaujon

The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care.

Key Points: 
  • The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care.
  • This dataset will enrich the data collected and enable the consortium to discover novel histological phenotypes of NASH in T2D patients.
  • Its multivendor platform, FibroNest, is delivered worldwide via the cloud and used in multiple pre-clinical and clinical studies across several fibrotic conditions.
  • For more information about FibroNest and PharmaNest, visit www.pharmanest.com and www.fibronest.com

Lytix Biopharma - Invitation to Capital Markets Day in Oslo, June 1, 2022

Retrieved on: 
Monday, August 15, 2022
CEO, Neoplasm, Assistant, Cancer, Squamous cell carcinoma, CMD, Board, University of Maryland School of Medicine, Malignancy, Research, Patient, CMO, Goldenberg, Immunology, Tumor microenvironment, Icahn School of Medicine at Mount Sinai, American Cancer Society, MD, BA, SCC, Doctor of Philosophy, Novartis, Temple University School of Medicine, Nasdaq, INSERM, The Westin Paris – Vendôme, Saint Joseph's University, Almirall, Generative art, General manager, Villanova University, Skin, La Salle University, BCC, Skin cancer, Mount Sinai Hospital, Stanford University, Maryland School, Therapy, Wake Forest University School of Business, MBA, University, Pharmaceutical industry, Medicine, Biology, Dermatology

OSLO, Norway, Aug. 15, 2022 /PRNewswire/ -- The CMD is a live event, open for physical attendance at Hotel Continental in Oslo, Norway, as well as a live webcast. It starts at 14.00 CET, and is expected to last approximately two hours, including Q&A.

Key Points: 
  • The core of Lytix' Biopharma's technology platform; eradiction of solid tumors
    Ted White, CEO of Verrica Pharmaceuticals Inc.
    Gary Goldenberg, CMO of Verrica Pharmaceuticals Inc.
  • In August 2020, Lytix Biopharma announced that it entered into a license agreement with Verrica to develop and commercialize LTX-315 for all malignant and pre-malignant dermatological indications (skin cancer).
  • Verrica intends to focus initially on basal cell and squamous cell carcinoma as the lead indications for development for LTX-315.
  • ystein Rekdal, CEO of Lytix Biopharma is co-founder of Lytix Biopharma and has extensive research background within tumor immunology, oncolytic peptides and their abilities to induce potent tumor specific immune responses.

Kura Oncology Reports Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, August 3, 2022
Neoplasm, Large-cell lung carcinoma, EGFR, Security (finance), Clinical trial, FTI, Medicine, NPM1, Head, AML, Patient, Company, Review, Tipifarnib, Nasdaq, U.S. Securities and Exchange Commission, Safety, FDA, Program, IND, News, Research, Investment, Pharmacokinetics, National Institute, KMT2A, INSERM, Cancer, Mixed-phenotype acute leukemia, KURA, NSCLC, Hand, Therapy, ID, GLOBE, Webcast, Breakthrough therapy, Data, HNSCC, Risk, Population, Pharmaceutical industry, Cryptocurrency, HRAS

ET

Key Points: 
  • ET
    SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2022 financial results and provided a corporate update.
  • Research and development expenses for the second quarter of 2022 were $24.3 million, compared to $21.1 million for the second quarter of 2021.
  • General and administrative expenses for the second quarter of 2022 were $11.1 million, compared to $12.6 million for the second quarter of 2021.
  • ET / 1:30 p.m. PT today, August 3, 2022, to discuss the financial results for the second quarter 2022 and to provide a corporate update.

HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer

Retrieved on: 
Monday, July 25, 2022
View, Multiple sclerosis, Pharmacology, Radiobiology, MIT Sloan School of Management, Hotspot, Industry, Protein, Universitate metro station, INSERM, Cell biology, Drug discovery, Therapy, Multimedia, Cancer, Biotechnology, MBA, Company, Biochemistry, Patient, Institute, Degenerative disease, Entrepreneurship, Pharmaceutical industry, Management, Novartis, Biology

BOSTON, July 25, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Paul Thibodeau, Ph.D., as Chief Business Officer.

Key Points: 
  • BOSTON, July 25, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Paul Thibodeau, Ph.D., as Chief Business Officer.
  • "We are very pleased to welcome Paul to HotSpot as Chief Business Officer," said Jonathan Montagu, Co-Founder and Chief Executive Officer of HotSpot Therapeutics.
  • Previously, he held numerous business development positions with increasing responsibilities at Sanofi Genzyme across its oncology, transplant and multiple sclerosis franchises.
  • HotSpot Therapeutics, Inc. is targeting naturally occurring pockets on certain proteins that it refers to as "natural hotspots" that are decisive in controlling cellular protein function.

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Retrieved on: 
Thursday, July 21, 2022
Health, FDA, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Newton, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intracerebral hemorrhage, VI, Brain, Mab, Mortality, Medicine, Food, A&B, ISIN, National Institute, EMA, CMO, Safety, GPVI, Thrombectomy, Stroke, ESOC, Clinical trial, European Medicines Agency, FDA, Standard of care, Patient, Infarction, General manager, IND, Pharmaceutical industry, INSERM

ACTICOR BIOTECH (Paris:ALACT) (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received "PRIority Medicines" status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.

Key Points: 
  • ACTICOR BIOTECH (Paris:ALACT) (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received "PRIority Medicines" status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.
  • The "PRIME" status granted by the European Medicines Agency (EMA) allows to reinforce the support for the development of drugs that target an unmet medical need.
  • This status will allow Acticor Biotech to strengthen interactions and obtain early dialogues with regulatory authorities in order to confirm the clinical development plan for glenzocimab in the treatment of stroke.
  • Yannick Pletan, General Manager & CMO of Acticor Biotech, said: "We are delighted that the European Medicines Agency has granted "PRIME" status to glenzocimab.

Children’s National Hospital Catherine Bollard selected to lead global Cancer Grand Challenges team taking on solid tumors in children

Retrieved on: 
Thursday, June 16, 2022
Survival, CAR, Stanford University School of Medicine, Cardiff University, Rhabdomyosarcoma, Disease, National, Hospital, Death, Cancer Research UK, U.S. News & World Report, Geography, GLOBE, National Cancer Institute, Time, Survivor, Immunology, Nursing, University College London, CEO, News, Degenerative disease, Grand Challenges, Stanford University, Program, No, Children's National Hospital, University college, Hope, Biostatistics, Institute, Good manufacturing practice, Lymphatic system, Harwell Science and Innovation Campus, Nextgen, Financial toxicity, Health, Mathematics, Human, Research, Proteomics, Center, Mobile phone, Vaccine, Pharmaceutical industry, Dietary supplement, Child, Cancer, INSERM, D.C

, director of the Center for Cancer and Immunology Research at Childrens National Hospital, has been selected to receive a $25m Cancer Grand Challenges award to tackle solid tumors in children.

Key Points: 
  • , director of the Center for Cancer and Immunology Research at Childrens National Hospital, has been selected to receive a $25m Cancer Grand Challenges award to tackle solid tumors in children.
  • With our Cancer Grand Challenge, we hope to bring next-generation CAR T-cell therapies to children with solid tumors, said Dr. Bollard.
  • The Cancer Grand Challenges NexTGen team, announced June 16, 2022, is taking on the initiatives Solid Tumours in Children challenge.
  • The Cancer Grand Challenges NexTGen team is funded by Cancer Research UK, the National Cancer Institute in the U.S. and The Mark Foundation for Cancer Research.

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline

Retrieved on: 
Monday, June 13, 2022
Olive, BTN, Leukemia, Macrophage, Company, Autoimmunity, CD3, McDermott Will & Emery, Investment, Venture round, Technology, Immune system, EUR, Early Bird, Family, Lists of publishing companies, Cancer, Degenerative disease, INSERM, Partnership, Climate, Phase, Antibody, Andera-ye Olya, Industry, Wellington Partners, Immunology, Carbon, Hematological Cancer Research Investment and Education Act, Leukemia & Lymphoma Society, CNRS, Initial public offering, Partner, University, CD8, Acceleration, Infection, Leadership, Research, Immunomodulation, LSP, IL-2, NK, T, Therapy, Growth, PD-1, Pharmaceutical industry, Vaccine, Financial services, Series, Butyrophilin, subfamily 1, member A1, Baring Emerging Europe, Health care

The Company also will apply the capital to investigate ICT01 in combination with other therapeutic agents, including IL-2, in the forthcoming EVICTION-2 clinical trial.

Key Points: 
  • The Company also will apply the capital to investigate ICT01 in combination with other therapeutic agents, including IL-2, in the forthcoming EVICTION-2 clinical trial.
  • The funding will accelerate the further advance toward the clinic of additional antibody candidates in immuno-oncology, auto-immune and infectious diseases.
  • In conjunction with the financing round, Florent Gros (Earlybird) and Raphal Wisniewski (Andera Partners) will join the Companys Board of Directors.
  • Hans Henrik Christensen, Chief Financial Officer of ImCheck Therapeutics, added, ImCheck has raised a total of EUR 154 million since inception.

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK™ Cell Engager antibody at EHA 2022 Congress

Retrieved on: 
Friday, June 10, 2022
European Hematology Association, Survival, Business, Multiple myeloma, Tripura Merger Agreement, GMP, Multimedia, Sale, Cellectis, HCC, Technology, Isatuximab, Antibody, Cancer, Cytolysis, Name, TALEN, INSERM, Cornerstone, Form, Pharmacokinetics, Ink, Forward-looking statement, Partnership, Laboratory, Securities & Exchange Commission of Pakistan, Communication, Daratumumab, Central Avenue, U.S. Securities and Exchange Commission, CD38, Business architecture, Annual report, Proxy, Glioblastoma, Cell adhesion, Plan, Patient, EHA, FLEX, SEC, MM, Research, LLC, NK, Lymphatic system, UCSF, Therapy, FDA, Prospectus, Myelocyte, NASDAQ, Clinical trial, Person, ADP, Congress, Vaccine, Fine chemical, Security (finance), Ownership, NCR1, Isleworth

AVENTURA, Fla. and NATICK, Mass., June 10, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the European Hematology Association's annual congress in Vienna, Austria on June 10th, 2022 is now available on both the EHA and Cytovia websites.

Key Points: 
  • CYT-338 showed greater dose dependent NK cell redirected cytolysis, degranulation, and cytokine production against MM1S cells compared to daratumumab.
  • CYT-338 showed minimal immune subset depletion, NK cell fratricide, and cytokine release compared to daratumumab in vitro.
  • Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.
  • Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms.

Faber-Castell and EnChroma make Father's Day colourful

Retrieved on: 
Wednesday, May 25, 2022
Arts, Museums, Men, General Health, Entertainment, Other Retail, Family, Optical, Specialty, Consumer, General Entertainment, Other Entertainment, Retail, Health, People, Color, UC, Medical research, National Institute, Multimedia, Woman, Common, University of California, Davis, Drawing, List of life sciences, Faber-Castell, CVD, NIH, Research, Color blindness, Creativity, INSERM, Man, University, San Francisco Bay Area, Prevalence, University of California, Berkeley, CEO, Cosmetics, Entertainment, EnChroma

EnChroma , creators of glasses for the colourblind, is partnering with Faber-Castell to launch a video campaign that recognises and celebrates all colourblind fathers on Father's Day.

Key Points: 
  • EnChroma , creators of glasses for the colourblind, is partnering with Faber-Castell to launch a video campaign that recognises and celebrates all colourblind fathers on Father's Day.
  • The special optical filters in EnChroma glasses help colourblind people perceive a wider range of colours and see colours more vividly, clearly and distinctly.
  • "The experience of colour is central to both EnChroma and Faber-Castell," says Erik Ritchie, CEO of EnChroma.
  • In 2020, EnChroma was awarded the San Francisco Bay Area's prestigious East Bay Innovation Award in the Life Sciences category.